95 related articles for article (PubMed ID: 10506693)
1. Phase II clinical trial of SKI-2053R, a new platinum analog, in the treatment of patients with advanced gastric adenocarcinoma.
Kim NK; Im SA; Kim DW; Lee MH; Jung CW; Cho EK; Lee JT; Ahn JS; Heo DS; Bang YJ
Cancer; 1999 Oct; 86(7):1109-15. PubMed ID: 10506693
[TBL] [Abstract][Full Text] [Related]
2. Influence of exposure and infusion times on the cytotoxicity and pharmacokinetics of cis-malonato[(4R, 5R)-4,5-bis(aminomethyl)-2-isopropyl-1,3-dioxolane]platinum(II) .
Kim HT; Kim DK; Cho YB; Kim TS; Jung I; Kim KH; Heo DS; Bang YJ; Shin SG; Kim NK
Cancer Chemother Pharmacol; 1998; 41(2):109-16. PubMed ID: 9443623
[TBL] [Abstract][Full Text] [Related]
3. A Phase I study of cis-malonato[(4R,5R)-4,5-bis(aminomethyl)-1,3-dioxolane] platinum(II) in patients with advanced malignancies.
Kim NK; Kim TY; Shin SG; Park YI; Lee JA; Cho YB; Kim KH; Kim DK; Heo DS; Bang YJ
Cancer; 2001 Apr; 91(8):1549-56. PubMed ID: 11301404
[TBL] [Abstract][Full Text] [Related]
4. Phase II trial of a novel platinum analog, SKI 2053R, in patients with previously untreated extensive-stage small-cell lung cancer.
Zang DY; Lee KH; Lee JS; Lee JH; Kim WK; Kim SH; Kim WD; Kim DS; Kim JH; Kim BS; Cho YB; Kim DK; Kim KH
Am J Clin Oncol; 1999 Oct; 22(5):495-8. PubMed ID: 10521066
[TBL] [Abstract][Full Text] [Related]
5. Antitumor activity of cis-malonato[(4R,5R)-4,5-bis(aminomethyl)-2- isopropyl-1,3-dioxolane]platinum(II), a new platinum analogue, as an anticancer agent.
Kim DK; Kim HT; Cho YB; Tai JH; Ahn JS; Kim TS; Kim KH; Hong WS
Cancer Chemother Pharmacol; 1995; 35(5):441-5. PubMed ID: 7850928
[TBL] [Abstract][Full Text] [Related]
6. In vitro antitumor activity of a new platinum complex, cis-malonato [(4R,5R)-4,5-bis(aminomethyl)-2-isopropyl-1,3-dioxolane] platinum (II) (SKI 2053R), against human lung and stomach cancer cell lines.
Hong WS; Kim HT; Kim KH; Kim DK
Anticancer Res; 1995; 15(1):51-4. PubMed ID: 7733640
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and antitumor activity of a new platinum compound, cis-malonato[(4R,5R)-4,5-bis(aminomethyl)-2-isopropyl-1, 3- dioxolane]platinum(II), as determined by ex vivo pharmacodynamics.
Kim DK; Kim HT; Tai JH; Cho YB; Kim TS; Kim KH; Park JG; Hong WS
Cancer Chemother Pharmacol; 1995; 37(1-2):1-6. PubMed ID: 7497577
[TBL] [Abstract][Full Text] [Related]
8. Phase II studies of BBR3464, a novel tri-nuclear platinum complex, in patients with gastric or gastro-oesophageal adenocarcinoma.
Jodrell DI; Evans TR; Steward W; Cameron D; Prendiville J; Aschele C; Noberasco C; Lind M; Carmichael J; Dobbs N; Camboni G; Gatti B; De Braud F
Eur J Cancer; 2004 Aug; 40(12):1872-7. PubMed ID: 15288289
[TBL] [Abstract][Full Text] [Related]
9. General pharmacology of cis-malonato[4R,5R)-4,5-bis-(aminomethyl)-2-isopropyl-1,3- dioxolane]platinum(II).
Kim DK; Ahn JS; Ryu G; Kim KH; Park CW; Kim MS; Chung MH; Shin SG; Suh YH; Kim YS
Arzneimittelforschung; 1994 Sep; 44(9):1080-8. PubMed ID: 7986249
[TBL] [Abstract][Full Text] [Related]
10. Phase II evaluation of iproplatin in patients with advanced gastric and pancreatic cancer.
Hubbard KP; Pazdur R; Ajani JA; Braud E; Blaustein A; King M; Llenado-Lee M; Winn R; Levin B; Abbruzzese JL
Am J Clin Oncol; 1992 Dec; 15(6):524-7. PubMed ID: 1449117
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of docetaxel and cisplatin combination chemotherapy in metastatic gastric cancer.
Park KW; Ahn JS; Park YS; Lee J; Kang JH; Park JO; Lim HY; Im YH; Kang WK; Park K; Lee SI
Cancer Chemother Pharmacol; 2007 Jan; 59(1):17-21. PubMed ID: 16721549
[TBL] [Abstract][Full Text] [Related]
12. Embryotoxic effects of SKI 2053R, a new potential anticancer agent, in rats.
Chung MK; Kim JC; Roh JK
Reprod Toxicol; 1998; 12(3):375-81. PubMed ID: 9628560
[TBL] [Abstract][Full Text] [Related]
13. Nephrotoxicity of heptaplatin: a randomized comparison with cisplatin in advanced gastric cancer.
Ahn JH; Kang YK; Kim TW; Bahng H; Chang HM; Kang WC; Kim WK; Lee JS; Park JS
Cancer Chemother Pharmacol; 2002 Aug; 50(2):104-10. PubMed ID: 12172973
[TBL] [Abstract][Full Text] [Related]
14. [FOLFOX regimen in the patients with locally advanced or metastatic gastric cancer].
Yan D; Dai H
Zhonghua Zhong Liu Za Zhi; 2009 Mar; 31(3):217-9. PubMed ID: 19615264
[TBL] [Abstract][Full Text] [Related]
15. Treatment of patients with upper gastrointestinal carcinomas.
Ajani JA
Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-72-S19-76. PubMed ID: 9427271
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus.
Ilson DH; Ajani J; Bhalla K; Forastiere A; Huang Y; Patel P; Martin L; Donegan J; Pazdur R; Reed C; Kelsen DP
J Clin Oncol; 1998 May; 16(5):1826-34. PubMed ID: 9586897
[TBL] [Abstract][Full Text] [Related]
17. Oxaliplatin combined with continuous infusion of 5-fluorouracil as first-line chemotherapy in patients with metastatic or recurrent gastric adenocarcinoma.
Lim JY; Cho JY; Oh KJ; Choi SH; Lee SI; Jeung HC
Chemotherapy; 2009; 55(4):200-6. PubMed ID: 19451710
[TBL] [Abstract][Full Text] [Related]
18. [Oxaliplatin combined with ELF regimen in the treatment of patients with advanced gastric cancer].
Lou F; Zhu YH; Pan HM
Zhonghua Zhong Liu Za Zhi; 2009 Jan; 31(1):75-8. PubMed ID: 19538878
[TBL] [Abstract][Full Text] [Related]
19. Oxaliplatin, irinotecan and cetuximab in advanced gastric cancer. A multicenter phase II trial (Gastric-2) of the Arbeitsgemeinschaft Medikamentose Tumortherapie (AGMT).
Wöll E; Greil R; Eisterer W; Bechter O; Fridrik MA; Grünberger B; Zabernigg A; Mayrbäurl B; Russ G; Dlaska M; Obrist P; Thaler J
Anticancer Res; 2011 Dec; 31(12):4439-43. PubMed ID: 22199312
[TBL] [Abstract][Full Text] [Related]
20. Epirubicin, cisplatin, oral UFT, and calcium folinate in advanced gastric carcinoma.
Kim YH; Kim BS; Seo JH; Choi CW; Kim JS; Chun HJ; Hyun JH; Kim JS
Oncology (Williston Park); 1999 Jul; 13(7 Suppl 3):64-8. PubMed ID: 10442365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
